Author: healthprofessionalradio

Dr. Michael Blaha, MD, MPH, Director of Clinical Research for the Prevention of Cardiovascular Disease at Johns Hopkins discusses detecting heart disease, current guidelines, adhering to treatment, and switching statins when a patient is no longer able to adhere to current therapy. LIVALO, a statin commonly used for high cholesterol, offers a Doctor Discussion Guide on its website that can help patients personalize their conversation with their doctor – whether in person or via telehealth – about their statin treatment options. 

Lisa Rose, SVP & Chief Marketing Officer with LifeScan, a diabetes management company discusses how they have teamed up with former professional football player and popular sports commentator, Mike Golic, to launch “Talking Type You“, a new campaign that not only acknowledges the personal discipline required to manage diabetes but also encourages open conversation about those realities. They will also introduce a new digital one-stop shop that offers wellness programs from experts like Noom, Fitbit, Cecelia Health, and Welldoc, and can be paired with glucose data from Bluetooth ®-connected OneTouch ® meters. 

Dr. Karen Noblett, MD, Chief Medical Officer at Axonics discusses a new innovative medical device called sacral modulation for the treatment of incontinence. She is joined by patient Jill Vanderbush who shares her experience with the sacral modulation device. 

Dr. Matthew Weir, Attending Physician and Director of the Division of Nephrology in the Department of Medicine at the University of Maryland Hospital discusses the large ADMIRAL trial that confirms AlloSure ® Kidney as an effective non-invasive diagnostic that can be used routinely in the surveillance setting to assess organ health. It is an improvement over the standard-of-care serum creatinine and has become an invaluable tool for nephrologists working to preserve donated kidneys, keeping patients healthy and off dialysis.

Dr. Elizabeth Profita, MD, a pediatric cardiologist at Stanford Children’s Health discusses how to weigh the risks and benefits of COVID-19 vaccination in different age groups, with a focus on the risk of myocarditis and whether myocarditis rates are expected to rise as boosters are rolled out to younger groups.

Murali Doraiswamy, MBBS, FRCP, Professor of Psychiatry and Behavioral Sciences at Duke University School of Medicine discusses recent findings from a survey released by Compass Pathways plc, a mental health care company, and Sermo, a global leader in physician insights, that showed two-thirds of doctors believe psilocybin therapy has potential therapeutic benefit, especially for patients with treatment-resistant depression.

Terry Hush, healthcare futurist, co-founder, and CEO of Roji Health Intelligence, a company that provides customized technology and data solutions to help healthcare providers succeed in value-based care, discusses how consumer-focused initiatives will greatly expand in 2022. As payers such as Medicare, health plans, and pharmaceutical companies expand efforts to align patients with primary or specialty providers with incentives for providing affordable health care, health systems will need to bridge the gap of consumer trust and data sharing to ensure their engagement in health system efforts, or face patient and financial losses under value-based reimbursements. 

Liz Homans, CEO of Lyell Immunopharma, discusses how the company is tackling one of the hottest topics in cancer treatment: how to deploy cell therapy techniques to improve outcomes for patients with solid tumor cancers. She talks about how the technologies Lyell has developed are enabling it to advance multiple types of cell therapies, the importance of manufacturing for advancing cell therapy, and the role advanced data and analytics capabilities and digital manufacturing processes may play in improving access to care. 

Dr. Melissa Barnett, an optometrist and internationally recognized key opinion leader, discusses the recent availability of  VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the first and only FDA-approved prescription eye drop to treat presbyopia or age-related blurry near vision in adults.

Theresa Bak-Thomsen, PhD, Director, Discovery Biologics at Novo Nordisk research center Seattle discusses her path to becoming a woman in leadership/STEM. She talks about how her multifaceted team is exploring new modes of action to discover potential new therapies and provides insight into what it takes to discover and develop new antibodies for medical conditions. She also discusses the broader scientific focus of the Novo Nordisk research center Seattle – the foundation of the company’s U.S. research development efforts for diabetes, obesity, liver disease, and other therapeutic areas.